Alprostadil (Caverject/MUSE) Manufacturer Copay Program: How to Cut Your Out-of-Pocket Cost

What Is Alprostadil and Why Does It Cost So Much?

Alprostadil is a synthetic form of prostaglandin E1 (PGE1) that works by relaxing smooth muscle in the penile vasculature, increasing blood flow to produce an erection. The FDA approved Caverject (intracavernosal injection) in 1995 and MUSE (medicated urethral system for erection) in 1997 for the treatment of erectile dysfunction (ED). Both formulations remain effective second-line options when oral PDE5 inhibitors like sildenafil or tadalafil fail or are contraindicated 1.

The cost problem is straightforward. Alprostadil is a biologically derived compound requiring cold-chain storage and specialized delivery devices. Brand-name Caverject Impulse runs $40 to $80 per single-use injection at most retail pharmacies, and patients using two to three doses per week can face monthly costs of $400 to $900 2. MUSE suppositories carry a similar per-unit price. Generic alprostadil injection exists, but even generics average $25 to $50 per dose without insurance.

The American Urological Association (AUA) 2018 guidelines on ED note that "intracavernosal injection of alprostadil is the most effective monotherapy for erectile dysfunction, with response rates exceeding 70%" 3. That clinical value means patients and prescribers frequently confront the tension between proven efficacy and real-world affordability.

How the Manufacturer Copay Program Works

The manufacturer copay assistance program for Caverject Impulse is designed to lower the out-of-pocket cost for patients who carry commercial (private) insurance. Eligible patients can reduce their copay to as little as $25 per prescription fill, with the program covering the remaining balance up to a maximum annual benefit. The specific dollar cap varies by program year and should be verified directly through Pfizer's patient support portal or by calling the number printed on the copay card.

Enrollment is simple. Patients download or request a copay savings card, present it alongside their insurance card at the pharmacy, and the discount applies automatically at the point of sale. Most cards activate within 48 hours of registration. The 2025-2026 iteration of the program is open to patients 18 years and older with a valid prescription and commercial insurance that covers alprostadil in some capacity 4.

Three groups are excluded from copay card programs by federal law: Medicare Part D beneficiaries, Medicaid recipients, and TRICARE enrollees. This restriction is not Pfizer-specific. The Anti-Kickback Statute prohibits manufacturer copay subsidies for federally funded insurance beneficiaries. Patients in these categories should look at patient assistance programs (PAPs) instead, which operate under different legal frameworks.

For MUSE specifically, Viatris (formerly Meda Pharmaceuticals) has operated its own savings program, though availability has been inconsistent since 2024. Patients prescribed MUSE should check the Viatris patient assistance page or call 800-657-7613 to confirm current enrollment windows.

Generic Alprostadil: A Faster Path to Savings

Switching from brand-name Caverject Impulse to a generic alprostadil injection is the single most effective cost-reduction step for most patients. Generic alprostadil for injection became available from multiple manufacturers after Pfizer's key patents expired. A 2023 analysis of GoodRx pricing data showed that generic alprostadil 20 mcg vials averaged $28 to $45 per dose at major retail chains, compared to $55 to $80 for brand Caverject Impulse at the same pharmacies 5.

Bioequivalence is not a concern here. The FDA requires all approved generic alprostadil products to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug 6. The active ingredient, concentration, route, and dosage form are identical. The injection device differs (generics typically use a standard vial-and-syringe system rather than the Caverject Impulse auto-injector), so patients may need brief retraining on reconstitution and injection technique.

Ask your prescriber to write the prescription for "alprostadil for injection" rather than specifying Caverject by brand. This permits the pharmacist to dispense whichever generic is in stock and priced lowest. Some state laws allow automatic generic substitution, but writing the prescription generically removes any ambiguity.

Compounding Pharmacy Options

Compounding pharmacies represent another significant cost pathway. A compounded alprostadil injection, often prepared as part of a "trimix" or "bimix" combination (alprostadil + papaverine, or alprostadil + papaverine + phentolamine), can cost $50 to $150 for a multi-dose vial that lasts weeks rather than a single use 7.

Trimix is the most commonly compounded erectile dysfunction injection in the United States. A 5 mL vial of standard trimix typically contains alprostadil 10 to 20 mcg/mL, papaverine 30 mg/mL, and phentolamine 1 mg/mL. At two to three uses per week, a single vial can last four to six weeks, bringing the effective per-dose cost to $3 to $10. That is a dramatic reduction from $40 to $80 per dose for single-use Caverject.

There are important distinctions between 503A and 503B compounding pharmacies. A 503A pharmacy compounds on a patient-specific basis with a valid prescription. A 503B outsourcing facility compounds in larger batches under FDA oversight and current good manufacturing practice (cGMP) standards 8. Both routes are legal and widely used for alprostadil compounds. Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and a leading authority on ED pharmacotherapy, has noted that "compounded intracavernosal combinations offer a well-established therapeutic alternative with decades of clinical use supporting their efficacy and safety profile" 9.

One trade-off: most commercial insurance plans will not cover compounded medications, so patients pay cash. Even so, the out-of-pocket cost for compounded trimix is typically lower than the copay on brand Caverject under many insurance plans.

Insurance Coverage Strategies for Alprostadil

Getting alprostadil covered by insurance requires understanding how formularies classify the drug. Most commercial plans place brand Caverject Impulse and MUSE on Tier 4 (specialty) or Tier 5 (non-preferred specialty), which means copays of $100 to $250 per fill even with insurance. Generic alprostadil injection usually sits on Tier 3 (non-preferred brand/generic), with copays of $40 to $75 10.

Prior authorization is common. Insurers typically require documentation that the patient has tried and failed at least one PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) before approving alprostadil. The AUA guidelines support this step-therapy approach, recommending oral PDE5 inhibitors as first-line treatment and intracavernosal injection as second-line therapy 3.

To improve your odds of approval, ask your prescriber to include the following in the prior authorization submission:

• Documentation of PDE5 inhibitor trial and failure (dates, doses, outcome)
• Any medical contraindication to oral PDE5 inhibitors (nitrate use, severe hypotension history)
• The specific alprostadil formulation and dose requested
• Clinical notes supporting medical necessity

If the first prior authorization is denied, appeal. A 2021 JAMA Internal Medicine study found that 39% to 59% of initial denials for specialty medications were reversed on first appeal, yet fewer than 10% of patients actually file appeals 11. Your prescriber's office can submit a peer-to-peer review with the plan's medical director, which carries substantially higher reversal rates than written appeals alone.

Patient Assistance Programs for Uninsured Patients

Manufacturer patient assistance programs (PAPs) differ from copay cards. Copay cards reduce the insured patient's cost share. PAPs provide the medication at no cost (or very low cost) to patients who lack insurance entirely or whose insurance does not cover the drug at all.

Pfizer's patient assistance program, Pfizer RxPathways, covers Caverject Impulse for qualifying uninsured patients. Eligibility criteria generally include U.S. residency, no prescription drug coverage for the requested medication, and household income at or below 400% of the federal poverty level ($62,400 for a single individual in 2026). Applications require a signed prescriber certification and proof of income 12.

Processing typically takes two to four weeks. Once approved, the medication ships directly to the prescriber's office or to a designated specialty pharmacy. Patients re-certify annually.

For patients who fall outside PAP income thresholds but still face high costs, several nonprofit organizations offer gap assistance. NeedyMeds and the Patient Access Network Foundation maintain databases of active copay assistance funds for urology and men's health medications. Availability fluctuates; funds open and close based on donations.

MUSE vs. Caverject: Cost Comparison

The two FDA-approved alprostadil delivery systems differ in cost, efficacy, and patient experience. Understanding these differences helps patients and prescribers choose the option with the best value.

MUSE (intraurethral suppository) delivers alprostadil directly into the urethra via a small applicator. The key trial by Padma-Nathan et al. published in the New England Journal of Medicine (N=1,511) reported that 65.9% of MUSE-treated men achieved erections sufficient for intercourse versus 18.6% with placebo 1. MUSE is available in 125 mcg, 250 mcg, 500 mcg, and 1,000 mcg strengths. Cash pricing runs $130 to $180 per box of six suppositories.

Caverject Impulse (intracavernosal injection) delivers alprostadil directly into the corpus cavernosum. Response rates in clinical trials exceeded 70% across dose ranges, with the 20 mcg dose producing erections in approximately 80% of treated patients 9. Cash pricing for a single 20 mcg injection ranges from $40 to $80.

On a per-dose basis, MUSE costs roughly $22 to $30 per suppository while Caverject runs $40 to $80 per injection. But MUSE has a lower per-dose response rate, meaning some patients need multiple attempts or higher doses. When accounting for efficacy-adjusted cost per successful erection, the two formulations converge. Patients who respond well to MUSE may save money over Caverject, but only if their dose requirement stays at 500 mcg or below.

Generic alprostadil injection undercuts both brand products. Compounded trimix undercuts everything.

Step-by-Step: Reducing Your Alprostadil Costs Today

Start with the option that applies to your situation and work down.

Step 1: Check your insurance formulary. Call the number on the back of your insurance card and ask which alprostadil products are covered, at what tier, and whether prior authorization is required. Request the specific copay amount for both brand and generic.

Step 2: Switch to generic if possible. If you are currently on brand Caverject, ask your prescriber to rewrite the prescription for generic alprostadil for injection. Savings average 30% to 50% compared to brand.

Step 3: Apply for the manufacturer copay card. If you carry commercial insurance, enroll in the Pfizer copay assistance program for Caverject or the Viatris program for MUSE. Present the card at every fill.

Step 4: Ask about compounding. If cost remains prohibitive, discuss compounded trimix or bimix with your urologist. Bring a list of 503B outsourcing facilities in your state. Many urology practices already have preferred compounding pharmacy relationships.

Step 5: Explore patient assistance. If you are uninsured or underinsured, apply to Pfizer RxPathways. Gather proof of income and have your prescriber complete the provider section of the application.

Step 6: Appeal any denial. If insurance denies coverage, file a formal appeal within 30 days. Request a peer-to-peer review between your prescriber and the plan's medical director.

Programs change frequently. Verify all enrollment details, income thresholds, and maximum benefit amounts directly with the manufacturer or your pharmacy before relying on any specific dollar figure quoted here. The Pfizer patient support line (800-717-1020) and the Viatris patient assistance line (800-657-7613) are the most reliable starting points as of mid-2026.